Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
$10.50
$10.46
$2.00
$10.50
$231.40M-4.81142,261 shsN/A
Icosavax, Inc. stock logo
ICVX
Icosavax
$15.31
$15.32
$4.75
$16.10
$766.88M1.281.22 million shsN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$1.91
-2.6%
$1.17
$7.80
$12.38
$32.95MN/A41,322 shs3.70 million shs
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$0.51
+5.7%
$0.50
$0.37
$3.18
$118.96M1.239.12 million shs5.02 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Icosavax, Inc. stock logo
ICVX
Icosavax
0.00%0.00%0.00%0.00%0.00%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
+50.77%+41.01%+71.93%+59.35%-44.00%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
+5.65%+3.70%+3.89%-27.69%+17.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Icosavax, Inc. stock logo
ICVX
Icosavax
N/AN/AN/AN/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
1.9596 of 5 stars
3.33.00.00.01.10.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
0.00
N/AN/AN/A
Icosavax, Inc. stock logo
ICVX
Icosavax
0.00
N/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00
N/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
2.67
Moderate Buy$4.50782.01% Upside

Current Analyst Ratings Breakdown

Latest CMPI, SGMO, JATT, and ICVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/14/2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $5.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/A$2.50 per shareN/A
Icosavax, Inc. stock logo
ICVX
Icosavax
$580K1,322.20N/AN/A$5.47 per share2.80
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/A$0.07 per share27.08($0.53) per shareN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$57.80M2.06N/AN/A$0.11 per share4.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/A
Icosavax, Inc. stock logo
ICVX
Icosavax
-$91.76M-$2.22N/AN/AN/AN/A-43.06%-39.53%N/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$6.85MN/A0.00N/AN/A-49.58%2.84%N/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$97.94M-$0.39N/AN/AN/A-124.61%-345.98%-79.86%8/5/2025 (Estimated)

Latest CMPI, SGMO, JATT, and ICVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$0.07N/AN/AN/A$31.68 millionN/A
5/12/2025Q1 2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/AN/A
Icosavax, Inc. stock logo
ICVX
Icosavax
N/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/A
5.20
5.20
Icosavax, Inc. stock logo
ICVX
Icosavax
N/A
18.06
18.06
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/A
0.15
0.15
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/A
0.76
0.76

Institutional Ownership

CompanyInstitutional Ownership
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
74.56%
Icosavax, Inc. stock logo
ICVX
Icosavax
92.59%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
47.97%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
56.93%

Insider Ownership

CompanyInsider Ownership
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
62.60%
Icosavax, Inc. stock logo
ICVX
Icosavax
30.59%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
20.00%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
2822.04 million8.24 millionNot Optionable
Icosavax, Inc. stock logo
ICVX
Icosavax
6050.09 million34.77 millionOptionable
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
317.25 million13.80 millionNot Optionable
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
480233.17 million223.61 millionOptionable

Recent News About These Companies

Sangamo cues up Fabry gene therapy filing on STAAR data

New MarketBeat Followers Over Time

Media Sentiment Over Time

Checkmate Pharmaceuticals stock logo

Checkmate Pharmaceuticals NASDAQ:CMPI

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Icosavax stock logo

Icosavax NASDAQ:ICVX

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

JATT Acquisition stock logo

JATT Acquisition NYSE:JATT

$1.91 -0.05 (-2.55%)
As of 07/18/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Sangamo Therapeutics stock logo

Sangamo Therapeutics NASDAQ:SGMO

$0.51 +0.03 (+5.65%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.50 -0.01 (-1.22%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.